Literature DB >> 234459

Solubilization and partial characterization of rat liver squalene epoxidase.

T Ono, K Bloch.   

Abstract

The microsomal enzyme system from rat liver which catalyzes squalene epoxidation requires a supernatant protein and phospholipids (Tai, H., and Bloch, K. (1972) J. Biol. Chem. 247, 3767). It has now been found that these two cytoplasmic components can be replaced by Triton X-100. The same detergent solubilizes the microsomal squalene epoxidase and the resulting supernatant can be separated into two components, A and B, by DEAE-cellulose chromatography. Neither Fraction A nor B alone has significant squalene epoxidase activity but combining the two affords a reconstituted system 5-fold higher in specific epoxidase activity than that of the original microsomes. FAD and Triton X-100 in addition to molecular oxygen and NADPH are required in the reconstituted system. Subjecting Fraction A to a second DEAE-cellulose chromatography does not change its specific activity but lowers NADH-ferricyanide reductase activity and the protoheme content to 1/25 and 1/4, respectively. When Fraction B was chromatographed on Sephadex G-200, the specific epoxidase activity tested in the presence of Fraction A was increased 3-fold. This procedure also raised the specific activity of NADPH-cytochrome c reductase activity in Fraction B 3-fold. The reconstituted epoxidase system is not inhibited by either carbon monoxide, potassium cyanide, or o-phenanthrolien but Tiron at 1 mM was inhibitory (50%). Erythrocuprein has no effect on epoxidation. No evidence has been found for the participation of hemoproteins (P450 or cytochrome b5) in squalene epoxidation. Component B appears to be identical with the flavoprotein NADPH-cytochrome c reductase. Component A may be a flavoprotein with an easily dissociable prosthetic group.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 234459

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

2.  Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.

Authors:  Yi Jin; Mo Chen; Trevor M Penning; Walter L Miller
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

3.  Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice.

Authors:  Xiu Jun Wang; Mark Chamberlain; Olga Vassieva; Colin J Henderson; C Roland Wolf
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

Review 4.  Enzymatic chemistry of cyclopropane, epoxide, and aziridine biosynthesis.

Authors:  Christopher J Thibodeaux; Wei-chen Chang; Hung-wen Liu
Journal:  Chem Rev       Date:  2011-10-21       Impact factor: 60.622

Review 5.  Intracellular sterol trafficking.

Authors:  M P Reinhart
Journal:  Experientia       Date:  1990-06-15

6.  Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.

Authors:  Christopher C Marohnic; Satya P Panda; Karen McCammon; José Rueff; Bettie Sue Siler Masters; Michel Kranendonk
Journal:  Drug Metab Dispos       Date:  2009-11-02       Impact factor: 3.922

7.  Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.

Authors:  Karen M McCammon; Satya P Panda; Chuanwu Xia; Jung-Ja P Kim; Daniela Moutinho; Michel Kranendonk; Richard J Auchus; Eileen M Lafer; Debashis Ghosh; Pavel Martasek; Rekha Kar; Bettie Sue Masters; Linda J Roman
Journal:  J Biol Chem       Date:  2016-08-05       Impact factor: 5.157

Review 8.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

9.  Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients.

Authors:  Taninee Sahakitrungruang; Ningwu Huang; Meng Kian Tee; Vishal Agrawal; William E Russell; Patricia Crock; Nuala Murphy; Claude J Migeon; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

10.  Studies on the mechanism of lanosterol 14 alpha-demethylation. A requirement for two distinct types of mixed-function-oxidase systems.

Authors:  F G Gibbons; C R Pullinger; K A Mitropoulos
Journal:  Biochem J       Date:  1979-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.